Gazyvaro in first-line FL
Follicular lymphoma (FL)
Gazyvaro in combination with chemotherapy, followed by Gazyvaro maintenance therapy in patients achieving a response, is indicated for the treatment of patients with previously untreated advanced FL.1
Gazyvaro in combination with bendamustine followed by Gazyvaro maintenance is indicated for the treatment of patients with FL who did not respond or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen.1
You can find information about Gazyvaro in R/R FL here.
Chronic lymphocytic leukaemia (CLL)
Gazyvaro in combination with chlorambucil is indicated for the treatment of adult patients with previously untreated CLL and with comorbidities making them unsuitable for full-dose fludarabine-based therapy.1
You can find information about Gazyvaro in CLL here.
1L, first-line; AE, adverse event; CLL, chronic lymphocytic lymphoma; FL, follicular lymphoma; FLIPI, Follicular Lymphoma International Prognostic Index; IRR, infusion-related reaction; MRD, minimal residual disease; PET, positron emission tomography; PFS, progression-free survival; QoL, quality of life; R/R, relapsed/refractory; SC, subcutaneous.
- Gazyvaro Summary of Product Characteristics.
Date of preparation: November 2019